Advertisement

Topics

Navamedic ASA: Q4 2017 results

02:00 EST 15 Feb 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
    Oslo, February 15, 2018 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 45.2 million in the fourth quarter of 2017, down from NOK 81.6 million in the same period in 2016, following the planned discontinuation of the Aspen agreement. Ex...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Navamedic ASA: Q4 2017 results "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...